{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T09:34:36Z","timestamp":1753522476326},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1002","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Current guidelines from large randomised trials recommend that all patients with diabetes type 2 or coronary artery disease after myocardial infarction should be treated with statin drugs. However, the recent 4D and CORONA trials show no improvement in mortality in elderly patients with ischaemic heart failure and patients with diabetes and end-stage renal disease receiving haemodialysis with the onset of statin treatment. The survival benefit from statin treatment appears to stem primarily from the prevention of progression of coronary artery disease. In clinical conditions where coronary artery disease does not significantly contribute to the cause of death statins seem to be less effective. In patients at risk for organ damage, statin treatment, therefore, has to be started early in the course of the disease. The effect of statin withdrawal in ischaemic heart failure or in patients with advanced renal disease is not known. On the basis of the available evidence, current statin treatment should not be stopped in these patients.<\/jats:p>","DOI":"10.1136\/hrt.2007.125013","type":"journal-article","created":{"date-parts":[[2008,8,14]],"date-time":"2008-08-14T17:31:07Z","timestamp":1218735067000},"page":"187-189","source":"Crossref","is-referenced-by-count":2,"title":["Who does not need a statin: too late in end-stage renal disease or heart failure?"],"prefix":"10.1093","volume":"85","author":[{"given":"U","family":"Laufs","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4t des Saarlandes , Homburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Custodis","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4t des Saarlandes , Homburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4t des Saarlandes , Homburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,5,5]]},"reference":[{"key":"2023041909145750500_b1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Group","year":"2002","journal-title":"Lancet"},{"key":"2023041909145750500_b2","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/01.CIR.102.16.1893","article-title":"Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project","volume":"102","author":"Sacks","year":"2000","journal-title":"Circulation"},{"key":"2023041909145750500_b3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"2023041909145750500_b4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2023041909145750500_b5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.hjr.0000277983.23934.c9","article-title":"European guidelines on cardiovascular disease prevention in clinical practice: full text","volume":"14","author":"Graham","year":"2007","journal-title":"Eur J Cardiovasc Prevent Rehabil"},{"key":"2023041909145750500_b6","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"2023041909145750500_b7","first-page":"3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","author":"National Cholesterol Education Program Expert Panel","year":"2002","journal-title":"National Heart, Lung, and Blood Institute, National Institutes of Health, Publication No 02-5215"},{"key":"2023041909145750500_b8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"2023041909145750500_b9","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"2023041909145750500_b10","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1136\/hrt.2005.085183","article-title":"American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively","volume":"92","author":"Mcelduff","year":"2006","journal-title":"Heart"},{"key":"2023041909145750500_b11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"2023041909145750500_b12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"2023041909145750500_b13","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"2023041909145750500_b14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/00365590500329304","article-title":"Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study","volume":"39","author":"Stegmayr","year":"2005","journal-title":"Scand J Urol Nephrol"},{"key":"2023041909145750500_b15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/j.ajkd.2003.09.012","article-title":"The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease","volume":"43","author":"Fathi","year":"2004","journal-title":"Am J Kidney D"},{"key":"2023041909145750500_b16","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"2023041909145750500_b17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2165\/00003495-200666020-00002","article-title":"HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk","volume":"66","author":"Laufs","year":"2006","journal-title":"Drugs"},{"key":"2023041909145750500_b18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cardiores.2005.03.021","article-title":"Cardiac effects of statins\u2014advancements and open questions","volume":"66","author":"Laufs","year":"2005","journal-title":"Cardiovasc Res"},{"key":"2023041909145750500_b19","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/hrt.2006.089797","article-title":"Heart failure: statins for all?","volume":"92","author":"Leite-Moreira","year":"2006","journal-title":"Heart"},{"key":"2023041909145750500_b20","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"2023041909145750500_b21","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/hrt.2006.110197","article-title":"Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice","volume":"93","author":"Choudhry","year":"2007","journal-title":"Heart"},{"key":"2023041909145750500_b22","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1161\/01.STR.0000240690.69406.28","article-title":"Discontinuation of statin treatment in stroke patients","volume":"37","author":"Endres","year":"2006","journal-title":"Stroke"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/85\/1002\/187\/50020307\/postgradmedj-85-187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/85\/1002\/187\/50020307\/postgradmedj-85-187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T09:37:18Z","timestamp":1681897038000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/85\/1002\/187\/7007417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,1]]},"references-count":22,"journal-issue":{"issue":"1002","published-online":{"date-parts":[[2009,5,5]]},"published-print":{"date-parts":[[2009,4,1]]}},"URL":"https:\/\/doi.org\/10.1136\/hrt.2007.125013","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,4]]},"published":{"date-parts":[[2009,4,1]]}}}